Alex Medick

Discover how AI and AMD GPUs are powering biotech innovation. Koosh Azimian shares his vision for curing cancer with AI by 2030.

Koosh Azimian on AI, Biotech, and the Future of Big Pharma on Beyond CUDA

AI isn’t just reshaping software, it’s beginning to rewrite the future of human health. Few people embody that convergence better than Koosh Azimian, serial entrepreneur, ex-Meta tech lead, and CEO of 310.AI, a company building foundation models for large biomolecules.

On this episode of Beyond CUDA, Koosh joins host Jeff Tatarchuk to discuss the AI race, biotech innovation, and how GPUs may hold the key to curing cancer by 2030.









Key Takeaways

1. The AI Race Isn’t Zero-Sum

Koosh brea

AI isn’t just reshaping software, it’s beginning to rewrite the future of human health. Few people embody that convergence better than Koosh Azimian, serial entrepreneur, ex-Meta tech lead, and CEO of 310.AI, a company building foundation models for large biomolecules.

On this episode of Beyond CUDA, Koosh joins host Jeff Tatarchuk to discuss the AI race, biotech innovation, and how GPUs may hold the key to curing cancer by 2030.









Key Takeaways

1. The AI Race Isn’t Zero-Sum

Koosh breaks down the state of play across major AI labs, from OpenAI and Anthropic to Meta, Google, and new challengers like xAI. He argues that “winning” isn’t about one model dominating, but about who can combine data, compute, innovation, and product execution most effectively.

2. GPUs as the Fuel for Discovery

Beyond LLMs, Koosh sees the biggest opportunities in angstrom-scale AI models, systems that can simulate molecules, proteins, and even quantum interactions. With enough GPU power, biology can be digitized, accelerating the path to new therapeutics.

3. From LLMs to Molecule Programming

Koosh envisions a world where AI can “program” molecules the way engineers program software. By modeling proteins and molecular interactions at unprecedented resolution, scientists could design drugs digitally before validating them in labs while cutting years and billions off development cycles.

4. Bridging Tech and Pharma Cultures

One of biotech’s biggest barriers isn’t just technical, it’s cultural. Koosh highlights the gap between fast-moving tech teams and cautious, risk-averse pharma organizations. The solution: AI platforms (AIP) that give biotech companies accessible, user-friendly tools to harness GPUs and models without reinventing the stack.

5. A Deadline for Cancer

Koosh is bold in his prediction: by 2030, AI will give us the tools to cure or mitigate more than 50% of cancers. The breakthrough lies in “molecule programming” using AI to design precise proteins and therapies that can interact with cells in programmable ways.


Wrapping Up

Koosh Azimian’s vision pushes us to think beyond chatbots and into the next frontier: using AI to reprogram life itself. From GPUs powering molecular simulations to platforms bridging pharma and tech, the convergence of AI and biotech could transform healthcare within the decade.

At Beyond CUDA, we believe the future of AI is bigger than language models, it’s about tackling humanity’s hardest problems. And with innovators like Koosh leading the charge, the path to curing cancer may be closer than we think.


About TensorWave

TensorWave is the AI cloud purpose-built for performance. Powered exclusively by Instinct™ Series GPUs, we deliver high-bandwidth, memory-optimized infrastructure that scales with your most demanding models—training or inference.

Ready to get started? Connect with a Sales Engineer.

TensorWave Welcomes the AMD Instinct™ MI355X

Koosh Azimian on AI, Biotech, and the Future of Big Pharma on Beyond CUDA

Subscribe to our Blog

Stay ahead of the curve with the latest in AI, AMD accelerators, and all things TensorWave.

Product

Resources

Company

© 2025 TensorWave Inc. - All rights reserved.